Sai Parenterals Ltd

Sai Parenterals Ltd has announced a book closure period from September 4th to September 10th, 2026, inclusive. This closure is for the purpose of the company's 25th Annual General Meeting (AGM), scheduled for September 10th, 2026, at 11:00 a.m. IST. The AGM will be conducted via Video Conference or Other Audio-Visual Means. The company has also fixed September 3rd, 2026, as the record date to identify shareholders eligible to vote electronically on the businesses to be transacted at the AGM.

Sai Parenterals Ltd has submitted its 25th Annual Report for the Financial Year 2025-26, in compliance with SEBI (LODR) Regulations, 2015. The report, dispatched to shareholders on August 19, 2026, details the company's evolution into an integrated pharmaceutical platform with strengths in branded generics and a scaling CDMO business. The company highlights its growing focus on injectables, R&D investments, and a manufacturing network with 1,160 million units of installed annual capacity across five facilities. International expansion through Noumed in Australia and New Zealand, including a renewed ₹1,300 Crore OTC medicines supply agreement, is also a key focus. The Annual General Meeting is scheduled for September 10, 2026, via Video Conference.

Sai Parenterals Ltd has announced its 25th Annual General Meeting (AGM) for the Financial Year 2025-26, scheduled for September 10, 2026, at 11:00 AM via Video Conference. The company has complied with SEBI (LODR) Regulations, 2015, by submitting the AGM notice. The annual report, dispatched on August 19, 2026, is available on the company's website. The report highlights the company's evolution into an integrated pharmaceutical platform with a strong foundation in branded generics and a growing CDMO business. Investments in R&D and manufacturing capabilities, including a network of five facilities with significant capacity, are aimed at expanding into regulated markets and advancing its injectables portfolio. The company also notes its international presence through Noumed and a renewed OTC medicines supply agreement in Australia.

Sai Parenterals Ltd announced its un-audited financial results for the quarter ended June 30, 2026. Consolidated revenue from operations stood at ₹178.7 crore, with total revenue at ₹182.4 crore. Gross profit was ₹76.2 crore (41.8% margin), EBITDA ₹27.3 crore (14.9% margin), and Profit After Tax (PAT) ₹7.9 crore (4.3% margin). The results reflect the full quarter consolidation of Noumed Pharmaceuticals. Standalone revenue was ₹56.2 crore, with PAT at ₹8.9 crore. The company also proposed a variation in IPO proceeds utilization to acquire majority stakes in two pharmaceutical assets, including a 60% stake in Saicriti Pharma Private Limited for ₹83.83 crore to build a critical-care injectable facility.

Sai Parenterals Ltd has filed a statement confirming no deviation or variation in the utilization of funds raised through its Initial Public Offer (IPO) for the quarter ended June 30, 2026. The company raised ₹2,850 million via IPO between March 24-27, 2026. The report details the allocation and utilization against original objects, including capacity expansion, R&D center establishment, loan repayment, working capital, and general corporate purposes. No significant deviations were noted in the utilization for the specified period.

Sai Parenterals' consolidated (primary) Q1 FY27 print was ₹178.7 Cr revenue and ₹7.9 Cr PAT (EPS ₹1.79), down 9.7% and 39.8% sequentially from ₹197.9 Cr revenue and ₹13.2 Cr PAT (EPS ₹4.02) in Q4 FY26. Reported YoY growth looks explosive (revenue +435%, PAT +460% versus a ₹33.4 Cr/₹1.4 Cr year-ago quarter) but that base predates the company's NSE/BSE listing on 2 April 2026, when it wasn't yet required to publish quarterly numbers — the comparison is not like-for-like and should not be read as underlying organic growth. On a sequential basis, which is the cleaner read here, the quarter was weak: both topline and profitability retreated from the prior quarter. The margin story is the bigger flag. Consolidated net margin compressed to 4.4% from roughly 6.6-6.65% in Q4 FY26, and derived EBITDA margin (PBT + finance cost + depreciation, over revenue) came in near 15.3% — below the 17% EBITDA margin management guided for FY27 at the May 2026 concall. Basis divergence is material: standalone net margin was 15.8% (PAT ₹8.9 Cr on ₹52.8 Cr revenue, EPS ₹2.01), more than 11 points above the consolidated 4.4%, meaning the overseas/subsidiary book (Noumed Pharmaceuticals Australia and other step-down units) is diluting group profitability sharply — a gap readers comparing the two statements will notice. We found no analyst consensus or brokerage preview specifically for Sai Parenterals (a small, recently-listed name; web search results conflated it with the separate, larger Sai Life Sciences), so vsStreet is unknown rather than assumed. Against management's own May-2026 guidance of ₹750 Cr FY27 revenue and 17% EBITDA margin, Q1's ₹178.7 Cr is close to but slightly below the ₹187.5 Cr quarterly run-rate implied by that target, and margin is running under the 17% goal — an early miss on the guidance pace management set out as confident and optimistic just one quarter ago. Management's own press release framed the print positively (revenue ₹182 Cr on a total-income basis, PAT ₹8 Cr, outlook 'neutral'), which is consistent with our figures but glosses over the sequential decline and margin compression. The quarter carried more corporate-action weight than usual: the board redirected ₹101.8 Cr of unused IPO proceeds — originally earmarked for organic upgradation of Units I/II (EU-GMP compliance) and a new R&D centre — into acquiring 60% stakes in Saicriti Pharma Private Limited (₹83.83 Cr, a greenfield sterile-injectables plant at Gummadidala, Hyderabad) and Prathyak Laboratories Private Limited (₹15 Cr, an existing pharma R&D platform with a 124-product pipeline), both targeted for completion before 30 October 2026. The board also approved incorporating a new US step-down subsidiary under its Singapore arm and related-party transactions (a funding loan and a sale-of-goods arrangement) with Noumed Pharmaceuticals Australia — the entity management has repeatedly cited as a growth driver — alongside director re-appointments/appointments and two resignations (a non-executive director and the company secretary) effective the same day.

Sai Parenterals Ltd has announced that its Board of Directors will convene on August 11, 2026. The primary agenda item is the consideration and approval of the un-audited financial results for the quarter ended June 30, 2026. Additionally, the board will review the Limited Review Report for the same period. The meeting will also address any other business as permitted by the Chair.

Sai Parenterals Limited held a board meeting on July 6, 2026, approving the appointment of M/s. Aakanksha Dubey & Co. as Secretarial Auditors for five financial years (2026-27 to 2030-31). M/s. NSVR & Associates LLP were appointed as Internal Auditors for FY 2026-27, and M/s. Sai Krishna & Associates as Cost Auditors for the same fiscal year. Additionally, the Chairman & Managing Director was authorized to explore strategic growth opportunities, both organic and inorganic. The meeting concluded at 03:10 p.m.

Sai Parenterals Limited held a board meeting on July 6, 2026, approving the appointment of M/s. Aakanksha Dubey & Co. as Secretarial Auditors for five financial years (2026-27 to 2030-31). M/s. NSVR & Associates LLP were appointed as Internal Auditors and M/s. Sai Krishna & Associates as Cost Auditors, both for FY 2026-27. The board also authorized the Chairman & Managing Director to explore growth opportunities. The meeting concluded at 3:10 PM.

Sai Parenterals' Australian subsidiary, Noumed Pharmaceuticals, has renewed its exclusive Over-The-Counter (OTC) medicines supply agreement with leading Australian pharmacy networks. The landmark 7½-year deal is valued at AUD 202 million (approximately INR 1300 crores), with an option for a further 3-year extension. The agreement includes adding 12 new products annually, enhancing the contract's value and scope. This renewal strengthens Noumed's position as a strategic supply partner and expands Sai Parenterals' international footprint, ensuring predictable, recurring revenues and enhancing manufacturing scale. The deal underscores confidence in Noumed's regulatory, quality, and supply chain capabilities in a highly regulated market.